| Document Date: 2014-10-09 14:57:16
Open Document File Size: 205,57 KBShare Result on Facebook
City Barcelona / Tarrytown / New York / Paris / / Company AMF / Regeneron Pharmaceuticals Inc. / ESC CONGRESS 2014 HOT LINE PRESS / Sanofi / REGENERON INVESTOR RELATIONS CONFERENCE CALL / Genzyme / / Country France / United States / United Kingdom / Spain / / / Event Company Listing Change / / IndustryTerm therapeutic solutions / consumer healthcare / science-based biopharmaceutical / healthcare / diabetes solutions / / MedicalCondition atopic dermatitis / colorectal cancer / diabetes / high cholesterol / rare inflammatory condition / CORONARY ARTERY DISEASE / hypercholesterolemia / rheumatoid arthritis / familial hypercholesterolemia / eye diseases / hypercholesterolemia / asthma / / Organization PCSK9 Development & Launch Unit / Congress / FDA / U.S. Securities and Exchange Commission / / Person Hala Mirza / Manisha Narasimhan / Sébastien Martel / / / Position integrated global healthcare leader / Private / / ProvinceOrState New York / / Technology therapeutic solutions / / URL www.regeneron.com / www.sanofi.com / /
SocialTag |
PRESS RELEASE Sanofi and Regeneron to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at ESC Congress 2014 Paris, France, and Tarrytown, NY, August 25, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY)